Articles tagged “503A”
7 articles
PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides
The FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 to evaluate 7 peptide compounds for 503A inclusion. Here's what they decided and what it means for patients, clinics, and the compounding industry.
Compounding Pharmacy Red Flags: How to Spot a Bad Actor
Not all compounding pharmacies are created equal. With the FDA issuing warning letters and the PCAC meeting approaching, here's how to identify legitimate pharmacies — and avoid dangerous ones.
How to Submit a Public Comment to the FDA Before July 9 (Step-by-Step)
The FDA's public comment period for the July 2026 PCAC meeting closes July 9. Here's exactly how to submit a comment on docket FDA-2025-N-6895 — and what to say if you're a patient, clinician, or researcher.
What Category 2 Removal Actually Means (And What It Doesn't)
The FDA removed 12 peptides from Category 2 in April 2026. Many people think this means they're legal to compound. It doesn't. Here's the critical legal nuance that most sources are getting wrong.
503A vs 503B: What's the Difference Between Compounding Pharmacies?
The terms 503A and 503B come up constantly in peptide therapy discussions, but most patients have no idea what they mean. Here's a clear breakdown of the two types of compounding pharmacies, how they're regulated, and why it matters for your peptide prescription.
The July 2026 PCAC Meeting: What's at Stake for BPC-157, TB-500, Semax, and More
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee will decide whether seven peptides — including BPC-157 and TB-500 — get formally authorized for compounding. Here's what the process looks like, what outcomes are possible, and what it means for patients and clinicians.
FDA Removes 12 Peptides from Category 2: What It Actually Means
On April 15, 2026, the FDA announced that 12 peptides — including BPC-157, TB-500, Semax, and Epitalon — will exit the Category 2 restricted list on April 22. Here's a clear breakdown of what changed, what didn't, and what happens next.